In a report released on August 13, Marc Goodman from Leerink Partners maintained a Buy rating on Stoke Therapeutics, with a price target of $18.00. The company’s shares closed yesterday at $17.17.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Goodman covers the Healthcare sector, focusing on stocks such as ACADIA Pharmaceuticals, Axsome Therapeutics, and Evolus. According to TipRanks, Goodman has an average return of 6.9% and a 50.30% success rate on recommended stocks.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Stoke Therapeutics with a $23.93 average price target, implying a 39.37% upside from current levels. In a report released yesterday, TR | OpenAI – 4o also reiterated a Buy rating on the stock with a $19.00 price target.
The company has a one-year high of $17.61 and a one-year low of $5.35. Currently, Stoke Therapeutics has an average volume of 681.4K.
Based on the recent corporate insider activity of 33 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of STOK in relation to earlier this year.
Read More on STOK:
- Stoke Therapeutics: Promising Outlook with Strong Financial Position and Advancing Clinical Trials Justifies Buy Rating
- Promising Developments in Stoke Therapeutics’ Clinical Trials Support Buy Rating
- Positive Outlook for Stoke Therapeutics: Promising Clinical Data and Strong Financial Position
- Stoke Therapeutics Advances RNA Medicine with Strong Q2 Results
- Stoke Therapeutics reports Q2 EPS (40c), consensus (54c)